In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...

Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

The Farawave NAV ablation catheter and the Faraview software are used with the Farapulse field ablation system to provide ...

Q3 2024 Earnings Call Transcript October 23, 2024 Boston Scientific Corporation beats earnings expectations. Reported EPS is ...

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

Boston Scientific Corp. posted another eye-popping quarterly report, led by a 177% year-over-year increase in its ...

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory ...

William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...

Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...

Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...